Appendix Table D-5Local therapies for unresectable colorectal cancer metastases to the liver—Summary of multivariable analyses in single-arm studies

Author - YearIndependent VariableModelAge (<64, ≥64)GenderECOG Status (0, ≥1)Primary Site (Colon, Rectum)Number of Radioembolization Treatments (1, ≥2)Extent of liver metastases (0–25%, 26–50%, 51–75%)Hepatic lobar involvement (unilobar, bilobar)Prior liver resection (No, Yes)Prior ablation (No, Yes)Extrahepatic disease (No, Yes)Number of lines of chemotherapy (≤2, >2)Radiation dose (<2, ≥2)Chemo-SIRT (No, Yes)Treatment Response (Unfavorable, favorable)CRC Stage at Liver Metastases Diagnosis (2/3, 4)Tumor Burden (0%–25%, 26%– 50%, 51%–75%, ≥76%)Tumor replacement (≤25%, >25%)Liver Metastases Diameter (≤3cm, >3cm)
Chua - 2011Overall SurvivalLog-rank test (univariate)0.4640.0340.1440.0080.0480.0050.6630.8590.3210.0630.0060.9650.017<0.001----
Overall SurvivalCox regression (multivariate)-0.275-0.0190.2530.512---0.0330.134-0.449<0.001----

CRC: colorectal cancer; ECOG: Eastern cooperative oncology group; SIRT: selective internal radiation therapy

From: Appendix D, Evidence Tables

Cover of Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer
Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer [Internet].
Comparative Effectiveness Reviews, No. 93.
Belinson S, Chopra R, Yang Y, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.